AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:25:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Seagate Technology Holdings PLC: A Significant Reduction in Stanley Druckenmiller's Portfolio
Thu 15 May 25, 11:25 PMWhy Teva Pharmaceuticals Stock Blasted 6% Higher Today
Mon 12 May 25, 09:02 PMTeva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?
Mon 12 May 25, 08:14 PMTeva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million
Thu 08 May 25, 05:43 PMTEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
Thu 08 May 25, 11:48 AMTeva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Thu 08 May 25, 10:16 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -3065.00000M | 658.00M | -4406.00000M | -1265.00000M | -2596.00000M |
| Minority interest | 53.00M | 39.00M | -109.00000M | -2.00000M | -322.00000M |
| Net income | -2353.00000M | 417.00M | -3990.00000M | -999.00000M | -2150.00000M |
| Selling general administrative | 1180.00M | 1099.00M | 1173.00M | 1192.00M | 1298.00M |
| Selling and marketing expenses | 2265.00M | 2429.00M | 2498.00M | 2614.00M | 2916.00M |
| Gross profit | 6973.00M | 7594.00M | 7725.00M | 7536.00M | 8296.00M |
| Reconciled depreciation | 1308.00M | 1330.00M | 1557.00M | 1722.00M | 1842.00M |
| Ebit | 2797.00M | 3198.00M | 3053.00M | 2797.00M | 1318.00M |
| Ebitda | 4105.00M | 4528.00M | 4610.00M | 3213.00M | 3160.00M |
| Depreciation and amortization | 1308.00M | 1330.00M | 1557.00M | 416.00M | 1842.00M |
| Non operating income net other | - | -1049.00000M | -696.00000M | -835.00000M | -1030.00000M |
| Operating income | 2797.00M | 3198.00M | 3053.00M | 2797.00M | -1637.00000M |
| Other operating expenses | 12235.00M | 12779.00M | 13601.00M | 14167.00M | 15985.00M |
| Interest expense | 966.00M | 1058.00M | 963.00M | 822.00M | 959.00M |
| Tax provision | -638.00000M | 211.00M | -168.00000M | -278.00000M | -195.00000M |
| Interest income | - | - | - | 825.00M | 894.00M |
| Net interest income | -966.00000M | -962.00000M | -963.00000M | -877.00000M | -985.00000M |
| Extraordinary items | - | - | - | - | -97.00000M |
| Non recurring | - | - | 4628.00M | - | 3027.00M |
| Other items | - | - | - | - | - |
| Income tax expense | -638.00000M | 211.00M | -168.00000M | -278.00000M | -195.00000M |
| Total revenue | 14925.00M | 15878.00M | 16658.00M | 16887.00M | 18854.00M |
| Total operating expenses | 4283.00M | 4495.00M | 4668.00M | 4816.00M | 5427.00M |
| Cost of revenue | 7952.00M | 8284.00M | 8933.00M | 9351.00M | 10558.00M |
| Total other income expense net | -5862.00000M | -2540.00000M | -7459.00000M | -4062.00000M | -4506.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2406.00000M | 447.00M | -4238.00000M | -987.00000M | -2401.00000M |
| Net income applicable to common shares | -2353.00000M | 417.00M | -3990.00000M | -999.00000M | -2399.00000M |
| Preferred stock and other adjustments | - | - | - | - | 249.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 44006.00M | 47666.00M | 50640.00M | 57470.00M | 60683.00M |
| Intangible assets | 6270.00M | 7466.00M | 8923.00M | 11232.00M | 14005.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 549.00M | 967.00M | 710.00M | 434.00M | 468.00M |
| Total liab | 35315.00M | 36422.00M | 39579.00M | 42407.00M | 44889.00M |
| Total stockholder equity | 7897.00M | 10278.00M | 10026.00M | 13972.00M | 14707.00M |
| Deferred long term liab | - | - | 964.00M | - | 2140.00M |
| Other current liab | 6020.00M | 903.00M | 931.00M | 890.00M | 804.00M |
| Common stock | 57.00M | 57.00M | 57.00M | 56.00M | 56.00M |
| Capital stock | 57.00M | 57.00M | 57.00M | 56.00M | 56.00M |
| Retained earnings | -12882.00000M | -10529.00000M | -10946.00000M | -6956.00000M | -5958.00000M |
| Other liab | 4394.00M | 3362.00M | 3205.00M | 3707.00M | 3867.00M |
| Good will | 17633.00M | 20040.00M | 20624.00M | 24846.00M | 24917.00M |
| Other assets | 1894.00M | -1.00000M | 1.00M | 1.00M | 1099.00M |
| Cash | 2801.00M | 2165.00M | 2177.00M | 1975.00M | 1782.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11469.00M | 11027.00M | 13164.00M | 13674.00M | 14322.00M |
| Current deferred revenue | 1453.00M | 7012.00M | 7289.00M | 8721.00M | 9449.00M |
| Net debt | 18760.00M | 21294.00M | 24221.00M | 25367.00M | 27134.00M |
| Short term debt | 2109.00M | 1426.00M | 3188.00M | 2345.00M | 2216.00M |
| Short long term debt | 2109.00M | 1426.00M | 3188.00M | 2345.00M | 2216.00M |
| Short long term debt total | 21561.00M | 23459.00M | 26398.00M | 27342.00M | 28916.00M |
| Other stockholder equity | 23560.00M | 23433.00M | 23314.00M | 23184.00M | 23068.00M |
| Property plant equipment | 6158.00M | 5982.00M | 6296.00M | 6436.00M | 6868.00M |
| Total current assets | 12051.00M | 12573.00M | 13005.00M | 13464.00M | 13794.00M |
| Long term investments | - | - | - | - | 61.00M |
| Net tangible assets | -16006.00000M | -17228.00000M | -19521.00000M | -22106.00000M | -24215.00000M |
| Short term investments | - | - | - | 957.00M | 991.00M |
| Net receivables | 3696.00M | 4529.00M | 4581.00M | 5676.00M | 5822.00M |
| Long term debt | 19103.00M | 21617.00M | 22731.00M | 24562.00M | 26700.00M |
| Inventory | 3833.00M | 3818.00M | 4403.00M | 4422.00M | 4731.00M |
| Accounts payable | 1887.00M | 1686.00M | 1756.00M | 1718.00M | 1853.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 966.00M | 1035.00M | 1091.00M | 1087.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2838.00000M | -2683.00000M | -2399.00000M | -2312.00000M | -2459.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 57.00M | 57.00M | 56.00M | 56.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -10529.00000M | -10946.00000M | -6956.00000M | -5958.00000M |
| Treasury stock | - | -4128.00000M | -4128.00000M | -4128.00000M | -4142.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 441.00M | 515.00M | 538.00M | 591.00M | 731.00M |
| Deferred long term asset charges | - | - | - | 386.00M | 368.00M |
| Non current assets total | 31955.00M | 35094.00M | 37634.00M | 44005.00M | 46889.00M |
| Capital lease obligations | 349.00M | 416.00M | 479.00M | 435.00M | - |
| Long term debt total | - | - | 22731.00M | 24562.00M | 26700.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 656.00M | 172.00M | 67.00M | 343.00M | 890.00M |
| Change to liabilities | 1914.00M | 764.00M | -463.00000M | 643.00M | -500.00000M |
| Total cashflows from investing activities | 656.00M | 1523.00M | 863.00M | 1355.00M | 1866.00M |
| Net borrowings | -1369.00000M | -1675.00000M | -1880.00000M | -1863.00000M | -3272.00000M |
| Total cash from financing activities | -1487.00000M | -2172.00000M | -1885.00000M | -241.00000M | -3351.00000M |
| Change to operating activities | -828.00000M | -1701.00000M | -2188.00000M | -1416.00000M | -1437.00000M |
| Net income | -2406.00000M | 456.00M | -4099.00000M | 76.00M | -2472.00000M |
| Change in cash | 636.00M | 21.00M | 202.00M | 734.00M | 819.00M |
| Begin period cash flow | 2198.00M | 2177.00M | 1975.00M | 1241.00M | 963.00M |
| End period cash flow | 2834.00M | 2198.00M | 2177.00M | 1975.00M | 1782.00M |
| Total cash from operating activities | 1590.00M | 798.00M | 1216.00M | 538.00M | 2446.00M |
| Issuance of capital stock | - | - | - | - | 0.00000M |
| Depreciation | 1308.00M | 1330.00M | 1557.00M | 416.00M | 1842.00M |
| Other cashflows from investing activities | - | 1913.00M | 1374.00M | 1537.00M | 1627.00M |
| Dividends paid | - | - | - | -52.00000M | 22.00M |
| Change to inventory | -163.00000M | 380.00M | 41.00M | 271.00M | 26.00M |
| Change to account receivables | 334.00M | -574.00000M | -293.00000M | -394.00000M | 88.00M |
| Sale purchase of stock | - | - | - | -1975.00000M | -1782.00000M |
| Other cashflows from financing activities | -118.00000M | 5668.00M | 545.00M | 2040.00M | 4117.00M |
| Change to netincome | 1378.00M | 729.00M | 6855.00M | 1925.00M | 5776.00M |
| Capital expenditures | 548.00M | 562.00M | 578.00M | 119.00M | 651.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | -3988.00000M | -4570.00000M | -1899.00000M | -2700.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 149.00M | 194.00M | 177.00M | 961.00M |
| Change in working capital | 1257.00M | -1701.00000M | -2188.00000M | -112.00000M | -1823.00000M |
| Stock based compensation | 124.00M | 119.00M | 129.00M | 20.00M | 155.00M |
| Other non cash items | 2366.00M | 714.00M | 6513.00M | 471.00M | 5581.00M |
| Free cash flow | 1042.00M | 236.00M | 638.00M | 419.00M | 1795.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TEVA Teva Pharma Industries Ltd ADR |
0.02 0.06% | 31.52 | - | 4.27 | 0.78 | 1.68 | 1.96 | 2493.26 |
| ZTS Zoetis Inc |
-1.87 1.53% | 120.49 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.56 2.23% | 25.64 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.64 2.02% | 128.01 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.14 0.77% | 18.21 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
124 Dvora Hanevi?a Street, Tel Aviv, Israel, 6944020
| Name | Title | Year Born |
|---|---|---|
| Mr. Kare Schultz | Pres, CEO & Director | 1961 |
| Mr. Eliyahu Sharon Kalif | Exec. VP & CFO | 1973 |
| Mr. Eric Drape | Exec. VP of Global Operations | 1962 |
| Mr. Mark Sabag | Exec. VP of International Markets Commercial | 1971 |
| Dr. Sven Dethlefs Ph.D. | Exec. VP of North America Commercial | 1969 |
| Mr. Amir Weiss | Sr. VP & Chief Accounting Officer | 1977 |
| Mr. Kevin C. Mannix | Sr. VP of Investor Relations | NA |
| Mr. David M. Stark | Exec. VP & Chief Legal Officer | 1969 |
| Kathleen Veit | Sr. VP, Global Compliance & Ethics Officer | NA |
| Mr. Eli Shani | Exec. VP of Global Marketing & Portfolio | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...